Gastroenterology

CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263

CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263

Source link

Related posts

Diet-induced adaptive thermogenesis requires neuropeptide FF receptor-2 signalling

Newsemia

Measles resurgence may pose unique threat to patients with inflammatory diseases

Newsemia

Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy